Coronary disease & ACS

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study

Eur Heart J Acute Cardiovasc CarePublished Secondary analysis of the PROMETHEUS prospective registry

Primary result · MACEResult — go to the resultHazard ratio 1.85 95% CI 1.71–2.00

Authors' conclusion

High thrombotic risk, as defined by the 2020 ESC NSTE-ACS guidelines, is highly prevalent among ACS patients undergoing PCI. The HTR definition had a strong prognostic impact, as it successfully identified patients at increased 1 year risk of ischaemic events.

Study context

Population
ACS patients undergoing percutaneous coronary intervention (PCI) discharged on prasugrel or clopidogrel
Participants
16,065 patients
Comparison
High thrombotic risk vs low-to-moderate thrombotic risk; prasugrel vs clopidogrel by thrombotic risk
  • High thrombotic risk (HTR)n = 4,293
  • Low-to-moderate thrombotic riskn = 11,772reference
Primary endpoint
MACE:
  • Death
  • MI
  • Stroke
  • Unplanned revascularization
Follow-up
1 year
Methodological detailsmulticentre, propensity score stratification
  • Multicentre
  • Propensity score stratification

Primary result

MACE

Hazard ratio

1.85

95% CI 1.71–2.00

P < 0.001

By group

HTR

23.3

%

Low-to-moderate risk

13.6%

HTRvs Low-to-moderate risk
HR 1.85 (95% CI 1.71–2.00); P < 0.001

As reported in the abstract

HTR prevalence
26.7%

Further findings

OutcomeadjHR (95% CI)
MACE, prasugrel vs clopidogrel, by thrombotic risk (subgroup) · 1 yearPrasugrelvs ClopidogrelHTR0.83 (0.68–1.02)
MACE, prasugrel vs clopidogrel, by thrombotic risk (subgroup) · 1 yearPrasugrelvs ClopidogrelLow-to-moderate risk0.75 (0.64–0.88)
  • Major adverse cardiac events (MACE), prasugrel vs clopidogrel, by thrombotic risk (subgroup): pinteraction = 0.32

Original publication

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. Eur Heart J Acute Cardiovasc Care. Published 18 July 2023. doi:10.1093/ehjacc/zuad083

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.